UTHR Add to watchlist $577.58 0.96 (-0.17%) Last updated: Apr 16, 2026 02:39
52-Week Range
$577.58
$272.12 $577.58 $607.89

Fundamentals Overview

United Therapeutics Corporation is near the high of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 20.7 PEG 1.77 P/B 3.61 P/S 7.95

Intrinsic value (DCF)

+27.2% upside vs price

Profitability

Net margin 41.9%

Risk (Beta)

0.75 — lower vol

Earnings & growth

EPS $27.86 Rev -1.2% Profit +7.6% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 74% confidence Risk: Lower Volatility — Beta 0.75. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +27.2% upside vs price · Analyst grade: B+ · 3M vs S&P 500: +19% · 3M vs Healthcare sector: +25.8%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$25.31B
P/E (TTM)
20.73
EPS (TTM)
$27.86
Dividend Yield
N/A
52-Week Range
$272.12 - $607.89
Volume vs Avg
N/A
Beta
0.75

About

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise abili...
Sector: Healthcare
Headquarters: US
Employees: 1,305
IPO Date: Jun 1999
Beta: 0.75 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Current institutional positions: Buy: 14, Equal Weight: 8, Neutral: 2, Outperform: 4, Overweight: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $734.42; current price is $577.58. That’s a +27.2% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 20.73
DCF value (model) $734.42 (27.2% upside)
PEG (TTM) 1.77
P/B (TTM) 3.61
P/S (TTM) 7.95
P/FCF (TTM) 24.32
Liquidity & enterprise
Current Ratio (TTM) 6.6
Quick Ratio (TTM) 6.28
Cash Ratio (TTM) 2.78
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 41.94%
Gross margin (TTM) 87.92%
Operating margin (TTM) 46.89%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for UTHR.

Analyst Sentiment at a Glance

B+
Buy 14Equal Weight 8Neutral 2Outperform 4Overweight 2
Price Target Consensus
Current $577.58
Median $600.00
Consensus $607.29
Low consensus $519.00
High consensus $700.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
Wells Fargo maintain Equal Weight Equal Weight 2026-03-31
HC Wainwright & Co. maintain Buy Buy 2026-03-31
B of A Securities maintain Neutral Neutral 2026-03-31
TD Cowen maintain Buy Buy 2026-03-30
Wells Fargo maintain Equal Weight Equal Weight 2026-03-23
Cantor Fitzgerald maintain Overweight Overweight 2026-03-12
UBS maintain Buy Buy 2026-03-05
Oppenheimer maintain Outperform Outperform 2026-02-26
HC Wainwright & Co. maintain Buy Buy 2026-02-26
Wells Fargo maintain Equal Weight Equal Weight 2026-02-26
TD Cowen maintain Buy Buy 2026-02-26
RBC Capital maintain Outperform Outperform 2026-02-26
UBS maintain Buy Buy 2026-01-06
UBS maintain Buy Buy 2025-11-06
Wells Fargo maintain Equal Weight Equal Weight 2025-10-30
RBC Capital maintain Outperform Outperform 2025-10-30
HC Wainwright & Co. maintain Buy Buy 2025-10-30
Morgan Stanley maintain Equal Weight Equal Weight 2025-10-10
UBS maintain Buy Buy 2025-09-29
Cantor Fitzgerald maintain Overweight Overweight 2025-09-10
HC Wainwright & Co. maintain Buy Buy 2025-09-05
Oppenheimer maintain Outperform Outperform 2025-09-05
UBS maintain Buy Buy 2025-09-04
Wells Fargo maintain Equal Weight Equal Weight 2025-09-03
B of A Securities maintain Neutral Neutral 2025-09-02
Jefferies maintain Buy Buy 2025-09-02
UBS maintain Buy Buy 2025-08-13
HC Wainwright & Co. maintain Buy Buy 2025-07-31
Wells Fargo maintain Equal Weight Equal Weight 2025-07-31